Alpha Teknova raises 2026 revenue guidance after record third quarter

Alpha Teknova, Inc. (Nasdaq: TKNO) reported third quarter 2026 results on November 4, 2026, announcing total revenue of $12.7 million for the quarter, up 22% over the same period a year earlier.¹ The company said it raised its 2026 revenue guidance to $46-48 million.¹

President and CEO Stephen Gunstream said the quarter marked the second consecutive quarter of record revenue¹ for the company, attributing growth to increased sales of products to life science tools, diagnostics and biopharma customers, with a notable increase in purchases of custom products by small and mid-sized biotech customers and their contract manufacturers, which the company said may signal improving biotech funding over the past four quarters.¹

On the balance sheet, Teknova disclosed that it closed an underwritten public offering on October 22, 2026, selling 9,200,000 shares of common stock at $5.00 per share, including full exercise of the underwriters' option, for gross proceeds of $46.0 million and net proceeds of approximately $42.9 million.¹ CFO Matt Lowell said the offering gave the company added balance sheet flexibility and brought in a significant number of new investors to Teknova's shareholder base.¹

The company also outlined a product update, saying it expanded its modular manufacturing platform with the launch of the Fill-Tek Dispensing System, which lets customers order specific single-use bag sizes, quantities and fill volumes across RUO, RUO+ and GMP grades without added turnaround time.¹

For the full year, Teknova said it now expects total revenue of $46 million to $48 million for fiscal 2026 and continues to anticipate Free Cash Outflow of less than $8 million for the year.¹ The company is scheduled to present at the Craig-Hallum Alpha Select Conference on November 17, 2026, and the Stephens Annual Investment Conference on November 18, 2026, as listed in its investor conference schedule.¹